Literature DB >> 20562265

Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells.

Marie-Ghislaine de Goër de Herve1, Bamory Dembele, Mélissa Vallée, Florence Herr, Anne Cariou, Yassine Taoufik.   

Abstract

Accumulating evidence suggests that CD4 help is needed at the memory stage to mount effective secondary CD8 T cell responses. In this paper, we report that memory CD4 T cells can provide efficient help to memory CD8 T cells after interaction of the two lymphocytes with distinct dendritic cells. Provision of help to CD8 T cells required direct cell-cell contact and involved both IL-2 and CD40 ligation, within a CD4-CD8 T cell synapse. Thus, following antigenic interaction with APCs, activated memory CD4 and CD8 T cells appear to separate from their respective APCs before meeting each other for help provision, regardless of their Ag specificity. CD4 help for memory CD8 T cells therefore appears to be conditioned primarily not by Ag specificity but by activation status.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562265     DOI: 10.4049/jimmunol.0904209

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).

Authors:  Jan F Mieves; Kirsten Wittke; Helma Freitag; Hans-Dieter Volk; Carmen Scheibenbogen; Leif G Hanitsch
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-05       Impact factor: 4.806

2.  FoxP3⁺ regulatory CD4 T cells control the generation of functional CD8 memory.

Authors:  M G de Goër de Herve; S Jaafoura; M Vallée; Y Taoufik
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

Review 3.  B cells and progressive multifocal leukoencephalopathy: search for the missing link.

Authors:  Deniz Durali; Marie-Ghislaine de Goër de Herve; Jacques Gasnault; Yassine Taoufik
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

4.  Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2+IFNγ- Thpp cells.

Authors:  Nan Deng; Jason M Weaver; Tim R Mosmann
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 5.  Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Authors:  Caroline Antoniol; Bruno Stankoff
Journal:  Front Immunol       Date:  2015-01-05       Impact factor: 7.561

6.  CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.

Authors:  Channakeshava Sokke Umeshappa; Roopa Hebbandi Nanjundappa; Yufeng Xie; Andrew Freywald; Yulin Deng; Hong Ma; Jim Xiang
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

7.  Th cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways.

Authors:  Channakeshava Sokke Umeshappa; Yufeng Xie; Shulin Xu; Roopa Hebbandi Nanjundappa; Andrew Freywald; Yulin Deng; Hong Ma; Jim Xiang
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

8.  Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Authors:  Junko Matsuzaki; Takemasa Tsuji; Immanuel F Luescher; Hiroshi Shiku; Junichi Mineno; Sachiko Okamoto; Lloyd J Old; Protul Shrikant; Sacha Gnjatic; Kunle Odunsi
Journal:  Sci Rep       Date:  2015-10-08       Impact factor: 4.379

Review 9.  Tissue competence imprinting and tissue residency of CD8 T cells.

Authors:  Roman Krzysiek; Marie-Ghislaine de Goër de Herve; Heng Yang; Yassine Taoufik
Journal:  Front Immunol       Date:  2013-09-17       Impact factor: 7.561

10.  Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Authors:  Diana Llopiz; Eduardo Huarte; Marta Ruiz; Jaione Bezunartea; Virginia Belsúe; Aintzane Zabaleta; Juan J Lasarte; Jesús Prieto; Francisco Borrás-Cuesta; Pablo Sarobe
Journal:  Oncoimmunology       Date:  2013-12-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.